Casdin Capital LLC Takes $12.67 Million Position in Septerna, Inc. (NASDAQ:SEPN)

Casdin Capital LLC acquired a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 553,268 shares of the company's stock, valued at approximately $12,670,000. Septerna makes up about 0.8% of Casdin Capital LLC's investment portfolio, making the stock its 20th biggest holding. Casdin Capital LLC owned approximately 1.25% of Septerna as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of SEPN. Tower Research Capital LLC TRC acquired a new stake in shares of Septerna in the fourth quarter valued at $25,000. New York State Common Retirement Fund bought a new position in shares of Septerna in the fourth quarter worth about $32,000. Legal & General Group Plc acquired a new position in shares of Septerna during the fourth quarter worth approximately $42,000. Summit Investment Advisors Inc. bought a new stake in shares of Septerna during the fourth quarter valued at approximately $45,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Septerna in the fourth quarter valued at approximately $52,000.

Insider Activity

In other news, Director Alan Ezekowitz acquired 7,491 shares of Septerna stock in a transaction dated Tuesday, March 4th. The stock was bought at an average cost of $6.35 per share, with a total value of $47,567.85. Following the completion of the transaction, the director now directly owns 24,911 shares of the company's stock, valued at approximately $158,184.85. This represents a 43.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Gil M. Labrucherie purchased 5,000 shares of Septerna stock in a transaction on Friday, February 21st. The shares were purchased at an average cost of $5.85 per share, with a total value of $29,250.00. Following the transaction, the chief financial officer now owns 30,000 shares in the company, valued at approximately $175,500. The trade was a 20.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 74,346 shares of company stock worth $439,670 in the last 90 days.

Wall Street Analyst Weigh In

A number of brokerages have commented on SEPN. Cantor Fitzgerald reiterated an "overweight" rating and issued a $50.00 price objective on shares of Septerna in a research report on Tuesday, February 11th. Wells Fargo & Company dropped their price objective on Septerna from $14.00 to $11.00 and set an "equal weight" rating for the company in a report on Friday, March 28th.

Septerna Stock Down 3.7 %

Shares of NASDAQ:SEPN traded down $0.26 during midday trading on Friday, hitting $6.69. The company had a trading volume of 164,758 shares, compared to its average volume of 411,644. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99. The firm has a fifty day simple moving average of $6.18 and a 200 day simple moving average of $14.55.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.13 million. Equities research analysts expect that Septerna, Inc. will post -7.11 earnings per share for the current year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.